N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment

Background Increasing evidence elucidated N6-methyladenosine (m6A) dysregulation participated in regulating RNA maturation, stability, and translation. This study aimed to demystify the crosstalk between m6A regulators immune microenvironment, providing a potential therapeutic target for patients with hepatocellular carcinoma (HCC). Methods Totals of 371 HCC 50 normal were included this study. GSE121248 GSE40367 datasets used validate expression HNRNPC. The R package “ConsensusClusterPlus” was performed screen consensus clustering types based on HCC. “pheatmap”, “immunedeconv”, “survival”, “survminer” “RMS” applied investigate expression, immunity, overall survival, clinical application different clusters groups. Comprehensive analysis HNRNPC pan-cancer conducted by TIMER2 database. Besides, mRNA protein verified qRT-PCR immunohistochemistry analysis. Results Most over-expressed excerpt ZC3H13 Three independent screened cluster 2 had favorable prognosis Then, positively macrophage, hematopoietic stem cell, endothelial stroma score, while negatively T cell CD4 + memory mast cell. We identified an prognostic factor HCC, nomogram superior value decision making. Moreover, PD-L1 significantly up-regulated tissues, 1, 3, we found correlated Patients high-expression groups associated tumor-promoting cells. prognosis, TMB, checkpoints cancers. Particularly, experiments confirmed that cells tissues. Conclusion play irreplaceable roles infiltration relationship possesses promising direction targets immunotherapy response. Exploration pattern could be build stratification individual move toward personalized treatment.